7XBB
Crystal structure of PDE4D catalytic domain complexed with compound 23a
7XBB の概要
| エントリーDOI | 10.2210/pdb7xbb/pdb |
| 分子名称 | Isoform 3 of cAMP-specific 3',5'-cyclic phosphodiesterase 4D, ZINC ION, MAGNESIUM ION, ... (5 entities in total) |
| 機能のキーワード | pde4 inhibitor, hydrolase |
| 由来する生物種 | Homo sapiens (human) |
| タンパク質・核酸の鎖数 | 2 |
| 化学式量合計 | 116637.35 |
| 構造登録者 | |
| 主引用文献 | Zhou, F.,Huang, Y.,Liu, L.,Song, Z.,Hou, K.Q.,Yang, Y.,Luo, H.B.,Huang, Y.Y.,Xiong, X.F. Structure-based optimization of Toddacoumalone as highly potent and selective PDE4 inhibitors with anti-inflammatory effects. Biochem Pharmacol, 202:115123-115123, 2022 Cited by PubMed Abstract: Phosphodiesterase-4 (PDE4) is an important drug target for inflammatory diseases. Previously, we identified a series of novel PDE4 inhibitors derived from the natural Toddacoumalone, among which the hit compound 2 with a naphthyridine scaffold showed moderate potency with the IC value of 400 nM. Based on the co-crystal structure of PDE4D-2, further structural optimizations and structure-activity relationship studies led to a highly potent PDE4 inhibitor 23a with the IC value of 0.25 nM and excellent selectivity profiles over other PDEs (>4000-fold). The co-crystal structure of PDE4D-23a elucidated that 23a has strong interactions with the M and Q pocket of PDE4D. Importantly, compound 23a significantly inhibits the release of inflammatory cytokines TNF-α and IL-6 in lipopolysaccharide-stimulated RAW264.7 cells. Thus, compound 23a with a naphthyridine scaffold is a promising PDE4 inhibitor for the treatment of inflammatory diseases. PubMed: 35688178DOI: 10.1016/j.bcp.2022.115123 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (2.10000900931 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






